The fact that anti-CTLA-4 improved vaccine efficacy in the B16 flank tumor model, but not in the GL261 intracranial model, is consistent with ICB therapy against brain tumors being limited by the ability of extracranially activated T cells to infiltrate into, and remain active in, the brain50. The gene discussed is CTLA4; the disease is brain neoplasm.